Spots Global Cancer Trial Database for Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

Official Title: CC-1088 Therapy for Chronic Lymphocytic Leukemia: A Phase I/II Trial

Study ID: NCT00006097

Conditions

Leukemia

Interventions

CC-1088

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CC-1088 in treating patients who have chronic lymphocytic leukemia that has not responded to previous therapy.

Detailed Description: OBJECTIVES: I. Determine the toxicity of CC-1088 in patients with refractory, progressive, B-cell chronic lymphocytic leukemia. II. Determine the response rate to this treatment in these patients. OUTLINE: Patients receive oral CC-1088 three times a day for 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 11-20 patients will be accrued for this study.